News

Home/News
News 2017-06-21T13:15:59+00:00
November 14, 2017
Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan ...
November 14, 2017
Albireo Reports Third Quarter 2017 Financial Results
BOSTON, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today reported ...
November 14, 2017
Zogenix to Present at Stifel 2017 Healthcare Conference
EMERYVILLE, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
November 13, 2017
Krystal Biotech Reports that KB103 Received Clearance From RAC Review and Announces Third Quarter 2017 Financial Results
PITTSBURGH, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS), a gene therapy company advancing “off-the-shelf,” topical and intra-dermal treatments for dermatological diseases, today ...
November 13, 2017
Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
November 13, 2017
TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget
SAN DIEGO, Nov. 13, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
November 13, 2017
Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs
SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) (the Company or Mirati), a clinical-stage targeted oncology company, today announced that it is reprioritizing ...
November 13, 2017
Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results
LIVONIA, Mich., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
November 13, 2017
Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017
REHOVOT, Israel, Nov. 13, 2017 (GLOBE NEWSWIRE) --  Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced financial results ...
November 13, 2017
AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update
Lausanne, Switzerland, November 13, 2017 - AC Immune SA (ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today ...
November 13, 2017
BioTime to Participate in Upcoming Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that ...
November 13, 2017
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on November 13, 2017
CRANBURY, N.J., Nov. 13, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases ...
November 13, 2017
Reata Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial and Operating Results
IRVING, Texas, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced financial results for the ...
November 13, 2017
Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference
PALO ALTO, Calif., Nov. 13, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that ...
November 13, 2017
CymaBay Therapeutics to Present at Three Investor Conferences
NEWARK, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
November 13, 2017
ADMA Biologics Announces Closing of $42M Follow-On Offering
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical ...
November 10, 2017
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
CAMBRIDGE, Mass., Nov. 10, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (VBIV) (VBV.TO) (VBI) today announced that Catalina Soare, VBI’s head of preclinical development, will ...
November 10, 2017
Kamada Announces Nomination of Three New Members to its Board of Directors
REHOVOT, Israel, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that the ...
November 10, 2017
Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis
SAN DIEGO, Nov. 10, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), today announced that it has completed full enrollment in the etrasimod Phase 2 study in ulcerative ...
November 9, 2017
Galmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
TEL AVIV, Israel, Nov. 9, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
Page 8 of 48